Trifecta Capital Advisors LLC Has $339,000 Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Trifecta Capital Advisors LLC increased its stock position in Gilead Sciences, Inc. by 766.9% in Q2, owning 3,060 shares valued at $339,000.
• Gilead reported $2.01 earnings per share for the last quarter, exceeding analysts' expectations, and set an FY 2025 EPS guidance of $7.95-$8.25.
• The biopharmaceutical company declared a quarterly dividend of $0.79, representing an annual yield of 2.7%, with a dividend payout ratio of 62.95%.

Trifecta Capital Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 766.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,060 shares of the biopharmaceutical company's stock after purchasing an additional 2,707 shares during the quarter. Trifecta Capital Advisors LLC's holdings in Gilead Sciences were worth $339,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Gilead Sciences by 12.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company's stock worth $1,541,302,000 after acquiring an additional 1,520,809 shares during the last quarter. Nuveen LLC bought a new stake in Gilead Sciences during the 1st quarter worth about $620,415,000. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Gilead Sciences by 12.5% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 3,742,656 shares of the biopharmaceutical company's stock worth $414,948,000 after acquiring an additional 417,237 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $118.25 on Thursday. The company has a market capitalization of $146.73 billion, a price-to-earnings ratio of 23.56, a P/E/G ratio of 0.79 and a beta of 0.34. The firm's 50 day simple moving average is $114.48 and its 200 day simple moving average is $110.12. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. Gilead Sciences's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is currently 62.95%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a "sector perform" rating in a research note on Wednesday. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, Citigroup raised their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $117.67.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,402,130 in the last ninety days. Company insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.